荃
02509
荃信生物－Ｂ
16.700
-0.320-1.88%Closed16:08 05/08 HKT
OPEN/PREV CLOSE18.180/18.280
TODAY RANGE17.800-18.500
VOL243.40K
MARKET CAP4.13B
52 WEEK RANGE10.800-36.500
AVG VOL (3M)309.90K
% TURNOVER0.11%
TURNOVER4.44M
P/E (TTM)11.740
% RANGE3.83%
EPS(TTM)1.550
P/E(FORWARD)18.164
P/B5.319
BVPS3.422
DIVIDEND--
P/S4.575
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP4.09B
SHARES OUTSTANDING227.07M
NEXT EARNINGS--
FREE FLOAT224.57M
LOT SIZE200
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·04/03 22:40
Shareholders Will Be Pleased With The Quality of Qyuns Therapeutics' (HKG:2509) Earnings
Simply Wall St·03/28 23:07
Qyuns Therapeutics (SEHK:2509) Profitability Shift Challenges Bearish Earnings Narratives
Reuters·01/07 14:09
Qyuns Therapeutics Repurchases HK$31.16 Million in Shares
Simply Wall St·01/06 00:50
Qyuns Therapeutics Co., Ltd. (HKG:2509) About To Shift From Loss To Profit
Reuters·12/22/2025 00:07
Qyuns Therapeutics Partners with Windward Bio Affiliate for Global Development of QX027N
Reuters·12/19/2025 14:00
Qyuns Therapeutics Co. Ltd. Held Extraordinary General Meeting
Reuters·12/09/2025 11:16
Qyuns Therapeutics Wins Ethics Approval for Phase I QX030N Trial in Australia
Reuters·12/03/2025 14:40
Qyuns Therapeutics Co. Ltd. Announces Date for Upcoming Extraordinary General Meeting
Reuters·11/25/2025 11:53
Qyuns Therapeutics Files HKEX Disclosure on Repurchase of 23,200 Shares for HKD 472,727.84
Reuters·11/21/2025 13:26
Qyuns Therapeutics Files HKEX Disclosure on Repurchase of 49,200 Shares for HKD 998,154.84
Reuters·11/20/2025 11:36
Qyuns Therapeutics Files HKEX Disclosure on Repurchase of 46,800 Shares for HKD 997,836.84
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.